Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010:64:23-41.
doi: 10.1146/annurev.micro.112408.134019.

Vaccines to prevent infections by oncoviruses

John T Schiller  1 , Douglas R Lowy
Affiliations
Review

Vaccines to prevent infections by oncoviruses

John T Schiller et al. Annu Rev Microbiol. 2010.

Abstract

It has been estimated that viruses are etiological agents in approximately 12% of human cancers. Most of these cancers can be attributed to infections by human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), Epstein-Barr virus (EBV), and Kaposi's sarcoma-associated herpesvirus (KSHV). Prophylactic vaccines against other pathogenic viruses have an excellent record as public health interventions in terms of safety, effectiveness, and ability to reach economically disadvantaged populations. These considerations should prompt efforts to develop and implement vaccines against oncoviruses. Safe and effective HBV and HPV vaccines, based on virus-like particles, are commercially available, and the major focus is now on vaccine delivery, especially to low-resource settings. HCV and EBV vaccines are under active development, but few clinical trials have been conducted, and none of the candidate vaccines has proven to be sufficiently effective to warrant commercialization. Efforts to develop KSHV vaccines have been more limited.

PubMed Disclaimer

References

    1. Adhikary D, Behrends U, Feederle R, Delecluse HJ, Mautner J. Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles. J Virol. 2008;82:3903–11. - PMC - PubMed
    1. Areste C, Blackbourn DJ. Modulation of the immune system by Kaposi’s sarcoma-associated herpesvirus. Trends Microbiol. 2009;17:119–29. - PubMed
    1. Barillari G, Ensoli B. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi’s sarcoma. Clin Microbiol Rev. 2002;15:310–26. - PMC - PubMed
    1. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudoparticles containing functional E1–E2 envelope protein complexes. J Exp Med. 2003;197:633–42. - PMC - PubMed
    1. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32(Suppl 1):S16–24. - PubMed

MeSH terms